The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Selective killing of candidate AML stem cells by antibody targeting of IL1RAP
Abstract
IL1RAP, a co-receptor for interleukin (IL)-1 and IL-33 receptors, was previously found to be highly upregulated on candidate chronic myeloid leukemia stem cells, allowing for leukemia-selective killing using IL1RAP-targeting antibodies. We analyzed IL1RAP expression in a consecutive series of 29 patients with acute myeloid leukemia (AML) and, based on the level of expression in mononuclear cells (MNCs), we divided the samples into 3 groups: IL1RAP low (n = 6), IL1RAP intermediate (n = 11), and IL1RAP high (n = 12). Within the CD34+CD38- population, the intermediate and high groups expressed higher levels of IL1RAP than did corresponding normal cells. With the aim to target AML stem cells, an anti-IL1RAP monoclonal antibody was generated followed by isotype switching for improved antibody-dependent, cell-mediated cytotoxicity activity. Using this antibody, we achieved selective killing of AML MNC, CD34+CD38+, and CD34+CD38- cells. Our findings demonstrate that IL1RAP is a promising new therapeutic target in AML.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Aberrant signaling via IL-1 and the downstream IRAK/TRAF pathway shared by IL-1R and TLRs has been implicated as a driver of survival and/or expansion of MDS and myeloid leukemia stem cells.
“Aberrant signaling via IL-1 and the downstream IL-1 receptor associated kinase/TNF receptor associated factor pathway shared by IL-1R and TLRs has been implicated as a driver of survival and/or expansion of MDS and myeloid leukemia stem cells (Ågerstam et al., 2016; Askmyr et al., 2013; Barreyro et al., 2012; Carey et al., 2017; Muto et al., 2020; Smith et al., 2019; Zhang et al., 2016).”
From PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress (2021) · cites this paper as Askmyr et al., 2013
Citations
Cites
Immunological and inflammatory functions of the interleukin-1 family
Dinarello, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132612 · Cited by 3,466
Rambaldi, A., Torcia, M., Bettoni, S., Vannier, E., Barbui, T., Shaw, A., Dinarello, C., & Cozzolino, F. (1991) · Blood · doi:10.1182/blood.v78.12.3248.3248 · Cited by 129
Flagged first, then by citations
Research works printed but not linked: 9
- Dinarello, 2012, Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases., Nat Rev Drug Discov, 11, 633, 10.1038/nrd3800 · DOI
- Järås, 2010, Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein., Proc Natl Acad Sci USA, 107, 16280, 10.1073/pnas.1004408107 · DOI
- Barreyro, 2012, Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS., Blood, 120, 1290, 10.1182/blood-2012-01-404699 · DOI · Paper page
- Estrov, 1992, Inhibition of acute myelogenous leukemia blast proliferation by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors., Blood, 79, 1938, 10.1182/blood.V79.8.1938.1938 · DOI
- Stosić-Grujicić, 1995, Modulation of acute myeloblastic leukemia (AML) cell proliferation and blast colony formation by antisense oligomer for IL-1 beta converting enzyme (ICE) and IL-1 receptor antagonist (IL-1ra)., J Chemother, 7, 67, 10.1179/joc.1995.7.1.67 · DOI
- Bonnet, 1997, Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell., Nat Med, 3, 730, 10.1038/nm0797-730 · DOI
- Taussig, 2008, Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells., Blood, 112, 568, 10.1182/blood-2007-10-118331 · DOI · Paper page
- Sarry, 2011, Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice., J Clin Invest, 121, 384, 10.1172/JCI41495 · DOI
- Eppert, 2011, Stem cell gene expression programs influence clinical outcome in human leukemia., Nat Med, 17, 1086, 10.1038/nm.2415 · DOI
Cited by
Sorted by citations
Carey, A., Edwards, D. K., Eide, C. A., Newell, L., Traer, E., Medeiros, B. C., Pollyea, D. A., Deininger, M. W., Collins, R. H., Tyner, J. W., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.018 · Cited by 270
Targeting microglia for the treatment of Alzheimer’s Disease
Wes, P. D., Sayed, F. A., Bard, F., & Gan, L. (2016) · Glia · doi:10.1002/glia.22988 · Cited by 185
Ramanan, V. K., Risacher, S. L., Nho, K., Kim, S., Shen, L., McDonald, B. C., Yoder, K. K., Hutchins, G. D., West, J. D., Tallman, E. F., et al. (2015) · Brain · doi:10.1093/brain/awv231 · Cited by 133
PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress
Chavez, J. S., Rabe, J. L., Loeffler, D., Higa, K. C., Hernandez, G., Mills, T. S., Ahmed, N., Gessner, R. L., Ke, Z., Idler, B. M., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201169 · Cited by 91
Metadata
- Authors
- Askmyr, M., Ågerstam, H., Hansen, N., Gordon, S., Arvanitakis, A., Rissler, M., Juliusson, G., Richter, J., Järås, M., & Fioretos, T.
- Affiliations
- Lund University (SE)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2013-05-02
- Volume
- 121
- Issue
- 18
- Pages
- 3709-3713
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2074711837
- Cited by
- 127
- References
- 2
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 9 · 2023: 10 · 2022: 16 · 2021: 15 · 2020: 10 · 2019: 7 · 2018: 8 · 2017: 13 · 2016: 5 · 2015: 10 · 2014: 6 · 2013: 3
- FWCI
- 5.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Keywords
- IL1RAP, acute myeloid leukemia, leukemia stem cells, antibody targeting, IL-33 receptor, monoclonal antibodies, antibody-dependent cellular cytotoxicity, CD34+CD38- cells, therapeutic target, selective killing
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antibodies, Antibody Specificity, Cells, Cultured, Cytotoxicity, Immunologic, Female, Humans, Immunotherapy, Male, Middle Aged, Neoplastic Stem Cells, Leukemia, Myeloid, Acute, Interleukin-1 Receptor Accessory Protein, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
